Tech Company Financing Transactions
Sesen Bio Funding Round
Sesen Bio closed a $35 million Series A venture capital round on 2/17/2010. Investors included Flagship Pioneering, Third Rock Ventures and private investors.
Transaction Overview
Company Name
Announced On
2/17/2010
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series A
Investors
Flagship Pioneering (Noubar Afeyan)
Third Rock Ventures (Third Rock)
Proceeds Purpose
The money and brainpower is being channeled into a company that seeks to engineer proteins with ideal properties for treating autoimmune diseases and blood clotting disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 First St. 1800
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Sesen Bio (formerly Eleven Biotherapeutics) is focused on developing innovative protein-based therapeutics to improve human health and treat diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Hurly
Chief Financial Officer
Richard Fitzgerald
Chief Scientific Officer
Gregory Adams
Chief Technical Officer
Glen MacDonald
Vice President
David Brooks
Browse more venture capital transactions:
Prev: 2/17/2010: NABsys venture capital transaction
Next: 2/17/2010: VuCast Media venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. All VC database entries reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs